7 research outputs found
Short-range charge-order in NiO perovskites (=Pr,Nd,Eu) probed by X-ray absorption spectroscopy
The short-range organization around Ni atoms in orthorhombic NiO
(=Pr,Nd,Eu) perovskites has been studied over a wide temperature range by Ni
K-edge x-ray absorption spectroscopy. Our results demonstrate that two
different Ni sites, with different average Ni-O bond lengths, coexist in those
orthorhombic compounds and that important modifications in the Ni nearest
neighbors environment take place across the metal-insulator transition. We
report evidences for the existence of short-range charge-order in the
insulating state, as found in the monoclinic compounds. Moreover, our results
suggest that the two different Ni sites coexists even in the metallic state.
The coexistence of two different Ni sites, independently on the ion,
provides a common ground to describe these compounds and shed new light in the
understanding of the phonon-assisted conduction mechanism and unusual
antiferromagnetism present in all NiO compounds.Comment: 4 pages, 3 figures, accepted PRB - Brief Report Dec.200
Assessing the impact of COVID-19 on liver cancer management (CERO-19).
BACKGROUND & AIMS: The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems and it may have heavily impacted patients with liver cancer (LC). Herein, we evaluated whether the schedule of LC screening or procedures has been interrupted or delayed because of the COVID-19 pandemic. METHODS: An international survey evaluated the impact of the COVID-19 pandemic on clinical practice and clinical trials from March 2020 to June 2020, as the first phase of a multicentre, international, and observational project. The focus was on patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma, cared for around the world during the first COVID-19 pandemic wave. RESULTS: Ninety-one centres expressed interest to participate and 76 were included in the analysis, from Europe, South America, North America, Asia, and Africa (73.7%, 17.1%, 5.3%, 2.6%, and 1.3% per continent, respectively). Eighty-seven percent of the centres modified their clinical practice: 40.8% the diagnostic procedures, 80.9% the screening programme, 50% cancelled curative and/or palliative treatments for LC, and 41.7% modified the liver transplantation programme. Forty-five out of 69 (65.2%) centres in which clinical trials were running modified their treatments in that setting, but 58.1% were able to recruit new patients. The phone call service was modified in 51.4% of centres which had this service before the COVID-19 pandemic (n = 19/37). CONCLUSIONS: The first wave of the COVID-19 pandemic had a tremendous impact on the routine care of patients with liver cancer. Modifications in screening, diagnostic, and treatment algorithms may have significantly impaired the outcome of patients. Ongoing data collection and future analyses will report the benefits and disadvantages of the strategies implemented, aiding future decision-making. LAY SUMMARY: The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems globally. Herein, we assessed the impact of the first wave pandemic on patients with liver cancer and found that routine care for these patients has been majorly disrupted, which could have a significant impact on outcomes
Population-based multicase-control study in common tumors in Spain (MCC-Spain): rationale and study design
Introduction: We present the protocol of a large population-based case-control study of 5 common tumors
in Spain (MCC-Spain) that evaluates environmental exposures and genetic factors.
Methods: Between 2008-2013, 10,183 persons aged 20-85 years were enrolled in 23 hospitals and primary
care centres in 12 Spanish provinces including 1,115 cases of a new diagnosis of prostate cancer,
1,750 of breast cancer, 2,171 of colorectal cancer, 492 of gastro-oesophageal cancer, 554 cases of chronic
lymphocytic leukaemia (CLL) and 4,101 population-based controls matched by frequency to cases by age,
sex and region of residence. Participation rates ranged from 57% (stomach cancer) to 87% (CLL cases) and
from 30% to 77% in controls. Participants completed a face-to-face computerized interview on sociodemographic
factors, environmental exposures, occupation, medication, lifestyle, and personal and family
medical history. In addition, participants completed a self-administered food-frequency questionnaire
and telephone interviews. Blood samples were collected from 76% of participants while saliva samples
were collected in CLL cases and participants refusing blood extractions. Clinical information was recorded
for cases and paraffin blocks and/or fresh tumor samples are available in most collaborating hospitals.
Genotyping was done through an exome array enriched with genetic markers in specific pathways. Multiple
analyses are planned to assess the association of environmental, personal and genetic risk factors
for each tumor and to identify pleiotropic effects.
Discussion: This study, conducted within the Spanish Consortium for Biomedical Research in Epidemiology
& Public Health (CIBERESP), is a unique initiative to evaluate etiological factors for common cancers
and will promote cancer research and prevention in Spain.The study was partially funded by the âAccion Transversal
del Cancerâ, approved on the Spanish Ministry Council on the
11th October 2007, by the Instituto de Salud Carlos III-FEDER
(PI08/1770, PI08/0533, PI08/1359, PS09/00773, PS09/01286,
PS09/01903, PS09/02078, PS09/01662, PI11/01403, PI11/01889,
PI11/00226, PI11/01810, PI11/02213, PI12/00488, PI12/00265,
PI12/01270, PI12/00715, PI12/00150), by the Fundación Marqués
de Valdecilla (API 10/09), by the ICGC International Cancer Genome
Consortium CLL, by the Junta de Castilla y LeĂłn (LE22A10-2), by
the ConsejerĂa de Salud of the Junta de AndalucĂa (PI-0571), by the
Conselleria de Sanitat of the Generalitat Valenciana (AP 061/10),
by the Recercaixa (2010ACUP 00310), by the Regional Government
of the Basque Country by European Commission grants FOOD-CT-
2006-036224-HIWATE, by the Spanish Association Against Cancer
(AECC) Scientific Foundation, by the The Catalan Government
DURSI grant 2009SGR1489
Structural evolution of the double perovskites Sr2B'UO6 (B' = Mn, Fe, Co, Ni, Zn) upon reduction: Magnetic behavior of the uranium cations
We describe the preparation of five perovskite oxides obtained upon reduction of Sr2BâČUO6 (BâČ = Mn, Fe, Co, Ni, Zn) with H2/N2 (5%/95%) at 900 °C during 8 h, and their structural characterization by X-ray powder diffraction (XRPD). During the reduction process there is a partial segregation of the elemental metal when BâČ = Co, Ni, Fe, and the corresponding BâČO oxide when BâČ = Mn, Zn. Whereas the parent, oxygen stoichiometric double perovskites Sr2BâČUO6 are long-range ordered concerning BâČ and U cations. The crystal structures of the reduced phases, SrBâČ0.5âxU0.5+xO3 with 0.37 < x < 0.27, correspond to simple, disordered perovskites; they are orthorhombic, space group Pnma (No. 62), with a full cationic disorder at the B site. Magnetic measurements performed on the phase with BâČ = Zn, indicate uncompensated antiferromagnetic ordering of the U5+/U4+ sublattice below 30 K.Fil: Pinacca, Ruben Miguel. Universidad Nacional de San Luis. Facultad de QuĂmica, BioquĂmica y Farmacia. Ărea QuĂmica General e InorgĂĄnica; ArgentinaFil: Viola, Maria del Carmen. Universidad Nacional de San Luis. Facultad de QuĂmica, BioquĂmica y Farmacia. Ărea QuĂmica General e InorgĂĄnica; ArgentinaFil: Pedregosa, Jose Carmelo. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Centro CientĂfico TecnolĂłgico Conicet - San Luis. Instituto de Investigaciones en TecnologĂa QuĂmica. Universidad Nacional de San Luis. Facultad de QuĂmica, BioquĂmica y Farmacia. Instituto de Investigaciones en TecnologĂa QuĂmica; Argentina. Universidad Nacional de San Luis. Facultad de QuĂmica, BioquĂmica y Farmacia. Ărea QuĂmica General e InorgĂĄnica; ArgentinaFil: Carbonio, Raul Ernesto. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Centro CientĂfico TecnolĂłgico Conicet - CĂłrdoba. Instituto de Investigaciones en FĂsico-quĂmica de CĂłrdoba. Universidad Nacional de CĂłrdoba. Facultad de Ciencias QuĂmicas. Instituto de Investigaciones en FĂsico-quĂmica de CĂłrdoba; ArgentinaFil: MartĂnez Lope, M. J.. Instituto de Ciencia de Materiales de Madrid; España. Consejo Superior de Investigaciones CientĂficas; EspañaFil: Alonso, J. A.. Instituto de Ciencia de Materiales de Madrid; España. Consejo Superior de Investigaciones CientĂficas; Españ
Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study
Background & aims: Information about the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with liver cancer is lacking. This study characterizes the outcomes and mortality risk in this population.
Methods: Multicentre retrospective, cross-sectional, international study of liver cancer patients with SARS-CoV-2 infection registered between February and December 2020. Clinical data at SARS-CoV-2 diagnosis and outcomes were registered.
Results: Two hundred fifty patients from 38 centres were included, 218 with hepatocellular carcinoma (HCC) and 32 with intrahepatic cholangiocarcinoma (iCCA). The median age was 66.5 and 64.5 years, and 84.9% and 21.9% had cirrhosis in the HCC and iCCA cohorts respectively. Patients had advanced cancer stage at SARS-CoV-2 diagnosis in 39.0% of the HCC and 71.9% of the iCCA patients. After a median follow-up of 7.20 (IQR: 1.84-11.24) months, 100 (40%) patients have died, 48% of the deaths were SARS-CoV-2-related. Forty (18.4%) HCC patients died within 30-days. The death rate increase was significantly different according to the BCLC stage (6.10% [95% CI 2.24-12.74], 11.76% [95% CI 4.73-22.30], 20.69% [95% CI 11.35-31.96] and 34.52% [95% CI 17.03-52.78] for BCLC 0/A, B, C and D, respectively; p = .0017). The hazard ratio was 1.45 (95% CI 0.49-4.31; p = .5032) in BCLC-B versus 0/A, and 3.13 (95% CI 1.29-7.62; p = .0118) in BCLC-C versus 0/A in the competing risk Cox regression model. Nineteen out of 32 iCCA (59.4%) died, and 12 deaths were related to SARS-CoV-2 infection.
Conclusions: This is the largest cohort of liver cancer patients infected with SARS-CoV-2. It characterizes the 30-day mortality risk of SARS-CoV-2 infected patients with HCC during this period
Outcome of liver cancer patients with SARSâCoVâ2 infection
Background & Aims:
Information about the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with liver cancer is lacking. This study characterizes the outcomes and mortality risk in this population.
Methods:
Multicenter retrospective, cross-sectional, international study of liver cancer patients with SARS-CoV-2 infection registered between February-December 2020. Clinical data at SARS-CoV-2 diagnosis and outcomes were registered.
Results:
Two-hundred-fifty patients from 38 centers were included, 218 with hepatocellular carcinoma (HCC), 32 with intrahepatic cholangiocarcinoma (iCCA). Median age was 66.5 and 64.5 years, and 84.9% and 21.9% had cirrhosis in the HCC and iCCA cohorts, respectively. Patients had advanced cancer stage at SARS-CoV-2 diagnosis in 39.0% of the HCC and 71.9% of the iCCA patients.
After a median follow-up of 7.20 [IQR:1.84â11.24] months, 100 (40%) patients have died,48% of the deaths were SARS-CoV-2-related.
Forty (18.4%) HCC patients died within 30-days. The death rate increase was significantly different according to the BCLC stage [6.10%(95%CI 2.24â12.74), 11.76%(95%CI 4.73â22.30), 20.69%(95%CI 11.35â31.96), and 34.52%(95%CI 17.03â52.78) for BCLC 0/A, B, C and D respectively; p=0.0017]. The Hazard Ratio was 1.45 (95%CI 0.49â4.31; p=0.5032) in BCLC-B vs 0/A, and 3.13 (95%CI 1.29â7.62; p=0.0118) in BCLC-C vs 0/A in the Competing risk Cox regression model. Nineteen out of 32 iCCA (59.4%) died, 12 deaths related to SARS-CoV-2 infection.
Conclusions:
This is the largest cohort of liver cancer patients infected with SARS-CoV-2. It characterizes the 30-day mortality risk of SARS-CoV-2 infected patients with HCC during this period